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Abstract
Observational studies have suggested that 25-hydroxyvitamin D (25(OH)D) levels are associated with inflammatory markers. Most trials
reporting significant associations between vitamin D intake and inflammatory markers used specific patient groups. Thus, we aimed to
determine the effect of supplementary vitamin D using secondary data from a population-based, randomised, placebo-controlled, double-
blind trial (Pilot D-Health trial 2010/0423). Participants were 60- to 84-year-old residents of one of the four eastern states of Australia. They
were randomly selected from the electoral roll and were randomised to one of three trial arms: placebo (n 214), 750 μg (n 215) or 1500 μg (n
215) vitamin D3, each taken once per month for 12 months. Post-intervention blood samples for the analysis of C-reactive protein (CRP), IL-6,
IL-10, leptin and adiponectin levels were available for 613 participants. Associations between intervention group and biomarker levels were
evaluated using quantile regression. There were no statistically significant differences in distributions of CRP, leptin, adiponectin, leptin:
adiponectin ratio or IL-10 levels between the placebo group and either supplemented group. The 75th percentile IL-6 level was 2·8 pg/ml
higher (95 % CI 0·4, 5·8 pg/ml) in the 1500 μg group than in the placebo group (75th percentiles:11·0 v. 8·2 pg/ml), with a somewhat smaller,
non-significant difference in 75th percentiles between the 750 μg and placebo groups. Despite large differences in serum 25(OH)D levels
between the three groups after 12 months of supplementation, we found little evidence of an effect of vitamin D supplementation on cytokine
or adipokine levels, with the possible exception of IL-6.
Key words: Vitamin D: Supplementation: Cytokines: Adipokines
Chronic inflammation underlies many pathological processes
including several types of cancer(1), CVD(2) and autoimmune
disease(3). Animal and in vitro studies have identified a number
of mechanisms by which the most biologically active form of
vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D), may reduce
inflammation(4). For example, treatment with 1,25(OH)2D
suppresses the NF-κB pathway(5), thereby reducing down-
stream expression of pro-inflammatory cytokines. By acting as a
ligand-activated transcription factor, the vitamin D receptor
(VDR) can also directly regulate cytokine gene transcription(6).
In addition, the VDR is expressed in adipocytes that are
responsible for the production of the adipokines adiponectin
and leptin. These have anti- and pro-inflammatory properties,
respectively, but investigations of the influence of 1,25(OH)2D
on their secretion are scarce(7,8).
Serum concentrations of the intermediate product
25-hydroxyvitamin D (25(OH)D) are used to measure a
person’s vitamin D status. Many observational studies suggest
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that 25(OH)D concentration is inversely associated with
pro-inflammatory markers and positively associated with
anti-inflammatory markers(9–14). For example, studies have
reported an inverse relationship between serum 25(OH)D levels
and circulating concentrations of C-reactive protein (CRP)(9,10),
IL-6(9) and leptin(11), and a positive association with adiponectin
levels(12–14). Other studies suggest a less straightforward rela-
tionship. Both pro- and anti-inflammatory cytokines levels were
found to be down-regulated in summer in association with
increased serum 25(OH)D levels(15). In contrast, an observational
analysis of data from a trial suggested that supplementation with
vitamin D increased the levels of both pro- and anti-inflammatory
cytokines in people with initially low serum 25(OH)D levels(16).
In some trials, supplementation with vitamin D has been
associated with significant reductions in circulating concentrations
of CRP(17,18) and IL-6(19,20), and significant increases in IL-10(21)
and adiponectin(22). However, most trials with significant results
were carried out in patients with a specific disease condition
rather than in ‘healthy’ participants. Results from trials that used
people without apparent disease were largely null, although these
used relatively small sample sizes (n 23–307)(23–29). A pooled
analysis of data from four trials, none of which was population-
based, found no significant change in CRP following high-dose
supplementation with vitamin D(30).
Many people without a specific disease may still have chronic,
low-grade inflammation, especially if exposed to toxic chemicals
(e.g. tobacco smoke), or if overweight or obese(31,32). Given the
possible consequences for the prevention of cancer and CVD, it is
worth investigating whether vitamin D supplementation can
dampen subclinical inflammation in apparently healthy people.
We used secondary data from our randomised controlled trial
(RCT) of vitamin D supplementation in a population-based
sample of older Australians, which demonstrated large effects of
supplementation on serum 25(OH)D(33), to assess the effect of
supplementary vitamin D on circulating inflammatory markers
(CRP, leptin, adiponectin, leptin:adiponectin ratio (LAR), IL-6 and
IL-10). To the best of our knowledge, this is one of the largest
and, hence, most highly powered studies of the possible effect of
vitamin D on inflammation, with relevance extending beyond
highly specific patient groups.
Methods
Study population and design
The methods and protocols of the study have been described(33).
Briefly, the Pilot D-Health trial 2010/0423 was a population-
based, randomised, placebo-controlled, double-blind chemopre-
vention trial of vitamin D3 in older adults. This study was
conducted according to the guidelines laid down in the 1964
Declaration of Helsinki, and all procedures involving human
subjects were approved by The Human Research Ethics
Committee at the QIMR Berghofer Medical Research Institute.
Written informed consent was obtained from all participants.
Participants consented to blood samples being stored indefinitely
and for them to be used in studies related to vitamin D. The QIMR
Berghofer Medical Research Institute Human Research Ethics
Committee approved the use of samples for this study.
We recruited 644 people aged 60–84 years who were resi-
dents of one of the four eastern states of Australia, using the
Australian Electoral Roll as the sampling frame. Participants
were sampled in strata of 5-year age bands, sex, state and
location of residence (capital city and elsewhere). We excluded
anybody who was taking ≥ 10 μg of vitamin D/d or who had a
history of kidney stones, hyperparathyroidism, osteomalacia,
osteoporosis or sarcoidosis. Recruitment took place between
October 2010 and March 2011, and 10 % of people invited were
randomised. Participants were randomly allocated to one of
three trial arms: placebo (n 214), 750 μg (n 215), or 1500 μg
(n 215) vitamin D3 (cholecalciferol), each taken once per month
for 12 months. Participants, study investigators and staff were
unaware of the treatment allocation until analysis of the primary
outcome (change in serum 25(OH)D level) was complete.
Approximately 95% of participants completed the study and
96% reported taking at least ten of their twelve study tablets.
Blood samples and laboratory analyses
Non-fasting blood samples were collected in serum separator
tubes at study entry and after the intervention period and
transported cold by overnight courier to the Queensland
University of Technology (Brisbane, Australia). Participants were
requested to provide a post-intervention blood sample within
2 weeks of the last tablet taken. Samples were centrifuged at 4°C
for 15min at 2000 g, and the serum was stored at –80°C.
Pre- and post-intervention serum 25(OH)D concentrations
were measured in a single batch using a commercial chemilu-
minescent immunoassay (LIAISON® 25(OH)D Vitamin D
TOTAL Assay; DiaSorin, Inc.). Intra- and inter-assay variabilities
were 3–6 and 6–9 %, respectively. The laboratory undertaking
the testing was certified by the international Vitamin D External
Quality Assessment Scheme.
We measured non-fasting serum levels of five inflammatory
markers in post-intervention blood samples: IL-6, IL-10, leptin,
adiponectin and CRP. Levels of IL-6, IL-10, leptin and
adiponectin were measured using commercial sandwich ELISA
kits (Merck Millipore) using a Multiskan Primary EIA V. 2.3
device with Labsystems Genesis V3.03 software, and levels of
CRP were measured using the high-sensitivity CardioPhase
hsCRP assay on the BNTM II system (Siemens Healthcare
Diagnostics). The inter- and intra-assay CV were <10 and <15 %
for all biomarkers. The minimum detectable concentrations for
IL-6, IL-10, leptin, adiponectin and CRP were 1·6 pg/ml, 2 pg/
ml, 0·78 ng/ml, 0·1 µg/ml and 0·175mg/l, respectively. All
assays for inflammatory markers were performed by Sullivan
Nicolaides Pathology (Indooroopilly, Australia) according to the
manufacturers’ instructions.
Questionnaires
Within 2 weeks of having blood drawn at study entry and exit,
participants were asked to complete questionnaires in which
they reported information about their height, weight, skin
phenotype, smoking and alcohol consumption, history of
cancer, diabetes or CVD, physical activity, time outdoors,
overall health and dietary intake of vitamin D.
694 M. Waterhouse et al.
Statistical analysis
We excluded participants for whom no blood sample was
available for the analysis of inflammatory markers. Cytokine
levels below the minimum detectable concentration were
assigned a value equal to the minimum detectable concentra-
tion for that biomarker. Adipokine levels outside the appro-
priate range of the assay were assigned the lower or upper
bound as appropriate. The LAR(34) was calculated by dividing
the leptin level (ng/ml) by the adiponectin level (µg/ml).
Comparisons of post-intervention levels of serum 25(OH)D
were made between intervention groups using two-sample
t tests. As biomarker distributions were right-skewed, we present
their descriptive statistics as median (interquartile range (IQR)).
We used quantile regression (QR) to evaluate the association
between intervention group and each biomarker level. QR is used
to model a specified percentile of a response variable, conditional
on one or more predictors. It is therefore similar to linear
regression, which models the conditional mean of the response
variable. The distribution of some biomarkers remained right-
skewed following a log transformation. QR makes no assump-
tions regarding the distribution of the regression residuals and
therefore offered an advantage over linear regression. Further, QR
was preferable to Wilcoxon’s rank sum test because it permitted
the inclusion of interaction terms.
We compared median levels of CRP, leptin, adiponectin and
LAR, and 75th percentile levels of IL-6 and IL-10. These were
meaningful comparisons given the shapes of biomarker
distributions. In particular, as IL-6 and IL-10 levels were very
right-skewed, we were interested in whether vitamin D
supplementation might have a dampening effect on more
‘extreme’ levels of these biomarkers.
Intervention group was treated as a categorical predictor in QR
models, with the placebo group used as the reference level. For
CRP, leptin, adiponectin and LAR, QR coefficients represent the
estimated difference in medians between an actively supple-
mented group (either the 750 or 1500 μg group) and the placebo
group. For IL-6 and IL-10, the coefficients represent the estimated
difference in 75th percentiles. 95 % confidence intervals for each
coefficient are interpreted in the usual way; a CI that does not
contain 0 indicates that the percentile differs significantly between
the placebo and supplemented groups. Wald’s statistic was used
to assess the overall significance of the intervention group. To test
for linear trends, we fitted models with intervention group treated
as a continuous variable, with the values 0, 1 and 2 corresponding
to the placebo, 750 and 1500 μg groups, respectively.
To test whether the effect of supplementation was modified
by sex, age (<70, ≥70 years), baseline BMI (<25, ≥25 kg/m2),
baseline serum 25(OH)D level (<30, ≥30 nmol/l) or time
between last tablet and collection of post-intervention blood
sample (≤7, >7 d), we included interaction terms for interven-
tion group by each predictor. The cutoff point of 30 nmol/l was
selected based on the Institute of Medicine’s 2011 report(35).
Analyses were repeated within strata of sex, age, baseline BMI,
baseline serum 25(OH)D level and timing of blood collection.
Analyses were performed in SAS version 9.2 (SAS Institute,
Inc.). All P values are two-sided, and we used a statistical sig-
nificance level of P< 0·05.
Sample size. The trial was designed to have adequate power to
assess changes in serum 25(OH)D levels(33). The final number
enrolled was greater than planned because of an increase in
response rate in later waves of recruitment.
Given strong recommendations against their use(36), post hoc
power calculations have not been performed for this secondary
analysis of inflammatory markers. This is, however, one of the
largest randomised placebo-controlled trials conducted to date




We randomised 644 participants, 615 of whom completed the
study. Post-intervention blood samples for the analysis of
inflammatory markers were available for 613 participants. The
median time between the last tablet taken and collection of the
post-intervention blood sample was 7 (IQR 6–11) d and, within
each treatment group, 93 % of people provided the sample
within 2 weeks of taking the final tablet. The average age of
participants included in this analysis was 72 (SD 7) years, and
46 % were women. Baseline characteristics are presented in
Table 1. Baseline serum 25(OH)D levels were similar for the
three groups (Table 1), whereas average post-intervention
serum 25(OH)D levels were highest in the 1500 μg group
(78 (SD 20) nmol/l), intermediate in the 750 μg group
(64 (SD 17) nmol/l) and lowest (unchanged) in the placebo
group (42 (SD 15) nmol/l)(33); P values for all pairwise
comparisons were <0·0001. The percentage of participants with
serum 25(OH)D levels >75 nmol/l also significantly differed
between groups (1500 μg group, 54 %; 750 μg group, 24 %;
placebo group, 1 %).
Analysis of inflammatory markers
Each of CRP, leptin, adiponectin and LAR had one missing
observation, and data were missing for IL-6 and IL-10 in four
and twelve cases, respectively. The percentages of observations
with a biomarker level below the limit of detection were 1 %
(CRP), 32 % (IL-6), 58 % (IL-10), 3 % (leptin) and 2 % (adipo-
nectin); the percentages did not differ between treatment
groups. The 75th percentile IL-6 level was 2·8 pg/ml higher
(95 % CI 0·4, 5·8 pg/ml) in the 1500 μg group than in the
placebo group (75th percentiles: 11·0 v. 8·2 pg/ml) (Table 2).
There was a somewhat smaller and non-significant difference
(in 75th percentile IL-6 levels) between the 750 μg and placebo
groups (Table 2). There were no statistically significant differ-
ences in median levels of CRP, leptin, adiponectin or LAR, or in
75th percentile levels of IL-10 levels, between the placebo
group and either the 750 or the 1500 μg group (Table 2).
There was a significant interaction between the intervention
group and age with respect to the association between
supplementation and median levels of leptin and LAR
(P interaction= 0·03 and 0·02, respectively) (online Supple-
mentary Table S1). For people aged <70 years, the median
leptin and LAR levels were higher in the 750 μg group and
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lower in the 1500 μg group compared with the placebo group.
The opposite pattern was observed for those aged at least 70
years. There were no other significant interactions.
Discussion
Despite large differences in serum 25(OH)D levels between the
three groups after 12 months of vitamin D supplementation, we
found little evidence of an effect of supplementation on levels
of cytokines and adipokines, with the possible exception of
IL-6. The significantly higher 75th percentile IL-6 level in the
1500 μg group compared with the placebo group was in
contrast to our expectations.
There have been at least ten RCT examining the effect of
vitamin D supplementation on IL-6 or IL-10 concentrations. Of
the RCT that included participants either without a specific
health condition(23–26) or that only included overweight or
obese participants(27–29), the results for IL-6 and IL-10 were all
essentially null. In one of these, there was a suggestion of a
greater change in median IL-10 levels in the supplemented
group (−70 %) than in the placebo group (−50 %), but the
difference was not significant after adjustment for multiple
testing(26). Possible explanations for these null results include
that the sample sizes were too small, the duration or dose of
supplementation was insufficient to elicit a response or that the
people studied had adequate vitamin D status at baseline.
Table 1. Baseline characteristics of participants by treatment group
(Mean values with their standard deviations; percentages)
Placebo (n 205) 750 μg (n 203) 1500 μg (n 205)
Variable Mean SD Mean SD Mean SD
Age (years) 71·5 6·8 71·6 7·0 71·5 6·8
BMI (kg/m2)* 27·5 4·7 27·3 4·6 27·2 4·1
Baseline serum 25(OH)D (nmol/l)† 42·0 13·5 41·6 12·7 41·9 14·3
Physical activity (METs/week) 45·7 45·2 46·6 49·1 46·0 52·7
Time outdoors (h/week) 14·0 12·0 15·0 12·7 14·7 12·3
Vitamin D intake (μg/d) 3·1 3·6 3·3 4·8 3·4 4·3
Sex (%)
Men 54·6 54·7 51·7
Women 45·4 45·3 48·3
Alcohol consumption (drinks/week) (%)
≤1 45·9 42·4 43·9
2–6 21·0 22·7 27·3
7–20 25·4 28·6 23·4
≥21 7·8 6·4 5·4
Smoking status (%)
Never smoker 57·1 58·1 60·0
Ex-smoker 38·5 35·5 36·1
Current smoker 4·4 6·4 3·9
Self-reported health status (%)
Good 85·9 88·2 86·8
Fair/poor 14·1 11·8 13·2
25(OH)D, 25-hydroxyvitamin D; MET, metabolic equivalent task.
* Missing data for one participant in the placebo group.
† Missing data for one participant in the 1500 μg group.
Table 2. Comparison of inflammatory markers following 12 months of monthly supplementation with placebo, or 750 or 1500 μg vitamin D3: quantile regression*
(Medians, interquartile ranges, b values and 95% confidence intervals)
Placebo (n 205) 750 μg vitamin D3 (n 203) 1500 μg vitamin D3 (n 205)
Variable Median IQR Median IQR b 95% CI Median IQR b 95% CI P† P trend‡
CRP (mg/l)§ 1·3 0·7–3·4 1·5 0·8–3·2 0·1 − 0·3, 0·5 1·4 0·8–3·4 0·1 − 0·3, 0·6 0·80 0·58
Leptin (ng/ml)§ 8·2 3·1–17·7 8·1 2·9–16·6 –0·1 − 2·8, 2·1 8·7 4·0–15·4 0·5 –2·4, 2·7 0·89 0·76
Adiponectin (µg/ml)§ 13·6 8·0–20·7 12·8 7·9–19·5 –0·9 –3·0, 1·4 12·6 7·8–19·6 –1·0 –2·7, 1·0 0·63 0·37
LAR§ 0·6 0·3–1·5 0·6 0·3–1·5 0·1 –0·2, 0·2 0·7 0·3–1·4 0·1 –0·1, 0·3 0·64 0·38
IL-6 (pg/ml)|| 4·0 1·6–8·2 4·5 1·6–9·6 1·4 –1·4, 4·5 4·6 1·6–11·0 2·8 0·4, 5·8 0·24 0·10
IL-10 (pg/ml)¶ 2·0 2·0–4·2 2·0 2·0–5·3 1·0 –1·2, 4·2 2·0 2·0–3·8 –0·3 –2·3, 2·2 0·55 0·68
IQR, interquartile range; CRP, C-reactive protein; LAR, leptin:adiponectin ratio.
* For CRP, leptin, adiponectin and LAR, quantile regression coefficients (denoted b) represent the estimated difference in medians between the actively supplemented group (750 or
1500 μg) and the placebo group. For IL-6 and IL-10, b represents the estimated difference in 75th percentiles.
† P value from the Wald test for intervention group treated as a categorical predictor (with 2 df), with the placebo group used as the reference level.
‡ P trend from the Wald test for intervention group treated as a continuous variable (1 df) with values 0, 1 and 2 corresponding to the placebo, 750 and 1500 μg groups, respectively.
§ Missing data for one participant in the placebo group.
|| Missing data for three participants in the placebo group and one participant in the 750 μg group.
¶ Missing data for four, three and five participants in the placebo, 750 and 1500 μg groups, respectively.
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However, for almost all of these trials, supplementation sig-
nificantly increased serum 25(OH)D levels(24–29), and in two
trials(25,28) participants had low baseline 25(OH)D levels.
It is not clear why, in the present study, the upper quartile
IL-6 level was greater for those receiving the highest dose of
vitamin D supplementation than in the placebo group, and it is
possible that this is a chance finding. It is also possible that
vitamin D supplementation might be detrimental at higher
doses. However, in addition to having pro-inflammatory effects,
there is also evidence that IL-6 exhibits anti-inflammatory
properties(37,38). Further, in some in vitro studies using human
cells, treatment with 1,25(OH)2D3 increased IL-6 production by
differentiated adipocytes(8), and induced a subpopulation of
IL-6-producing T cells when administered to T lymphocytes(39).
Results from trials measuring CRP have been mixed, with no
consistent evidence of any clinically relevant effect. In many
RCT in which participants did not have a specific disease, CRP
levels did not significantly change(23–25,27–29,40). Vitamin D
supplementation was associated with a significant reduction in
circulating concentrations of CRP in healthy pregnant
women(17) and in patients with a history of myocardial
infarction(18), but CRP levels increased in another trial among
people who were overweight or obese(41).
With respect to the adipokines, some observational studies
have reported positive associations between serum 25(OH)D
level and adiponectin levels(12,13), with one study using a
Mendelian randomisation approach to demonstrate that the
association was possibly causal(14). In contrast, an inverse
correlation has been observed between serum 25(OH)D levels
and circulating concentrations of leptin(11). Trial data concern-
ing adipokines are scarce and those that have been conducted
had small sample sizes(22,28,42). To the best of our knowledge,
only one trial has reported a significant increase in adiponectin
levels following vitamin D supplementation(22). The study was
restricted to participants with type 2 diabetes, and the end-
of-study adiponectin levels reported were much lower than in
our participants. We found no difference in levels of either
adipokine between placebo and active supplementation
groups. The significant interaction between the intervention
and age with respect to leptin and LAR levels is mostly likely a
chance finding, as there was no dose–response relationship in
stratified analyses.
Our results were largely null. For a given biomarker, this
means that either that the effect due to supplementation was
too small to be of biological importance or that the sample size
was insufficient to detect a small but potentially important
effect. The CI provide a range of plausible values for the actual
effect size.
Cytokine regulation may be dependent on the serum 25(OH)D
levels achieved by supplementation. The authors of a study that
showed that IL-6 production by human monocytes was inhibited
by treatment with ≥75 nmol/l (but not 37·5 nmol/l) 25(OH)D3,
concluded that maintaining a serum 25(OH)D level ≥75 nmol/l
was necessary for optimal anti-inflammatory effects(43). A small
observational study of young adults (25–42 years) also noted that
levels of selected pro-inflammatory cytokines were higher in
those with serum 25(OH)D levels ≤80 nmol/l when compared
with people with higher levels(44). Approximately one half of
our participants in the 1500 μg group achieved a post-
intervention serum 25(OH)D level ≥75 nmol/l, compared with
just 1 % in the placebo group. Thus, for comparisons between
the 1500 μg group and the placebo group, it seems unlikely that
our mostly null results are because of inadequate serum 25(OH)
D levels following supplementation.
This study has some limitations. Diet influences systemic
inflammation, and thus it was not ideal to have used non-fasting
blood samples. Although this has the potential to influence our
summary statistics, the randomisation eliminates any risk of
biased estimates of treatment effect that might have otherwise
resulted. Because we did not measure baseline levels of
inflammatory markers, we could not assess baseline equiva-
lence and could not analyse changes in levels. The lack of
baseline data is extremely unlikely to have led to any bias in
these results. The trial groups were extremely well balanced at
baseline(45), and it would be extraordinary if the distribution of
any biomarkers differed before the intervention. Thus, any
differences after the intervention are an indication of change
from baseline. We used a monthly bolus dose of vitamin D,
which some have argued might confer suboptimal benefits (for
some endpoints) when compared with daily dosing(46–48).
However, two studies found that daily or monthly dosing did
not produce significantly different serum 25(OH)D levels after
2 months(49) or 1 year(50) of vitamin D3 supplementation. Given
the relatively long half-life of vitamin D and 25(OH)D(51),
variability in timing of post-intervention blood samples should
also not be responsible for our largely null findings. Although
non-differential follow-up could introduce bias, our extremely
high completion rate (96 %) means that any bias would be
negligible and would not have materially influenced the results.
Caution should also be exercised in generalising our results, as
our population was older and predominantly (95 %) Caucasian.
Our study also has strengths. It is one of the largest rando-
mised placebo-controlled trials with measurement of inflam-
matory markers conducted to date, and, importantly, our
participants were recruited from the general population.
Consequently, our results may be more relevant to the general
elderly population than those from studies focusing on people
with specific diseases. The duration of our intervention and the
doses administered were sufficient to elicit measurable increa-
ses in serum 25(OH)D levels, and our study had high rates of
retention and adherence (96 % of participants reported taking at
least ten of the twelve study tablets).
With the possible exception of IL-6, we found little evidence
of an effect of vitamin D supplementation on cytokine or
adipokine levels. These results highlight the uncertainty
surrounding the effectiveness of vitamin D supplementation in
improving inflammatory biomarker profiles and the need to
better understand the effects of vitamin D supplementation
before recommending that it is routinely used in the general
population.
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